Soleno Therapeutics Files 8-K on Financials
Ticker: SLNO · Form: 8-K · Filed: 2024-11-06T00:00:00.000Z
Sentiment: neutral
Topics: financial-condition, results-of-operations, sec-filing
TL;DR
SOLENO files 8-K, expect financial updates soon.
AI Summary
On November 6, 2024, Soleno Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or operational updates were detailed in the provided text.
Why It Matters
This filing indicates Soleno Therapeutics is providing updates on its financial performance and condition to the SEC, which is crucial for investors to assess the company's health.
Risk Assessment
Risk Level: low — The filing is a standard 8-K reporting financial condition and results of operations, without immediate news of significant events.
Key Players & Entities
- SOLENO THERAPEUTICS INC (company) — Registrant
- November 6, 2024 (date) — Date of Report
- 100 Marine Parkway, Suite 400 Redwood City, CA 94065 (address) — Principal executive offices
- Capnia, Inc. (company) — Former company name
FAQ
What is the primary purpose of this 8-K filing for Soleno Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report on Soleno Therapeutics, Inc.'s Results of Operations and Financial Condition, as well as to provide Financial Statements and Exhibits.
On what date was this 8-K report filed?
This 8-K report was filed on November 6, 2024.
What is Soleno Therapeutics, Inc.'s principal executive office address?
Soleno Therapeutics, Inc.'s principal executive office is located at 100 Marine Parkway, Suite 400, Redwood City, CA 94065.
What was Soleno Therapeutics, Inc.'s former company name?
Soleno Therapeutics, Inc.'s former company name was Capnia, Inc.
Under which section of the Securities Exchange Act of 1934 is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 503 words · 2 min read · ~2 pages · Grade level 12 · Accepted 2024-11-06 16:17:01
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value SLNO NASDAQ Indicate by
Filing Documents
- d889134d8k.htm (8-K) — 23KB
- d889134dex991.htm (EX-99.1) — 83KB
- g889134g1106235601226.jpg (GRAPHIC) — 3KB
- g889134g1106235644255.jpg (GRAPHIC) — 3KB
- 0001193125-24-252054.txt ( ) — 243KB
- slno-20241106.xsd (EX-101.SCH) — 3KB
- slno-20241106_lab.xml (EX-101.LAB) — 18KB
- slno-20241106_pre.xml (EX-101.PRE) — 11KB
- d889134d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SOLENO THERAPEUTICS, INC. Date: November 6, 2024 By: /s/ Anish Bhatnagar Anish Bhatnagar Chief Executive Officer